CSF3 and diffuse large B-cell lymphoma: A total of 103 newly diagnosed patients with DLBCL were included for analysis, with 74 (71.8%) receiving primary G-CSF prophylaxis (prophylaxis group) and 29 (28.2%) not receiving primary G-CSF prophylaxis (non-prophylaxis group).